In September 2009, Osiris Therapeutics, Inc. (OSIR) reported preliminary results from two Phase III trials evaluating its Prochymal product candidate for the treatment of acute Graft-versus-Host disease [GVHD]. Unfortunately, neither trial reached its primary endpoint, sending shares from $14 to a 52-week low of $5.35 by November 2009. The results were the latest in a [...]
February 7, 2012
MD Becker Partners' newsletter covering the life science industry
Download the Life Science Digest App
Featured Video
Keynote address "Creating the methodological framework for cancer immunotherapy success" from MD Becker Partners' 2nd Annual Cancer Immunotherapy: A Long-Awaited Reality Conference:
About Life Science Digest
Life Science Digest is published by MD Becker Partners LLC, a boutique management and strategy consulting firm focusing on both public and private companies in the life science industry, including pharmaceuticals, biotechnology, and medical devices.
Interested in contributing articles to Life Science Digest? Send your request and a writing sample to: info@mdbpartners.com
- Slide 2
Article Tag Cloud
American Society of Clinical Oncology
Amgen
AMGN
ASCO
Astellas Pharma
AZN
Bavarian Nordic
BIIB
Biogen Idec
biotech
biotechnology
BMY
Bristol-Myers Squibb
CELG
Celgene
Celldex Therapeutics
Cell Therapeutics
CEPH
Cephalon
CTIC
CYCC
Cyclacel Pharmaceuticals
Dendreon
DNDN
FDA
GENZ
GlaxoSmithKline
GSK
ipilimumab
JNJ
Johnson & Johnson
LLY
NASDAQ Biotech Index
NBI
NVS
PFE
Pfizer
prostate cancer
PROSTVAC
Provenge
roche
Sanofi-Aventis
Seattle Genetics
SGEN
SNY
Like Us on Facebook
Copyright © 2012 MD Becker Partners LLC · WordPress · Log in
Follow MD Becker Partners